Tucker Quirk

Vp, Business Development at Dragonfly Therapeutics

Tucker Quirk has a diverse work experience spanning across various companies and roles. Tucker began their career as a Summer Research Intern at Nanyang Technological University in 2012, followed by a position as an Undergraduate Research Assistant at Clemson University from 2012 to 2013. In 2015, they joined Torreya as an Analyst and worked there until 2018. During this time, they gained valuable experience in the financial sector. In 2018, Tucker moved to Nomura, where they served as an Associate in Healthcare IB until 2019. Tucker then joined HealthCare Royalty Partners as an Associate from 2019 to 2021. In 2021, Tucker started a new chapter in their career by joining Skyhawk Therapeutics as part of their Business Development team. Later in 2021, they also took on a role at Dragonfly Therapeutics, Inc. as their Senior Director of Business Development. Tucker'swork experience showcases their expertise and growth in the business development and finance sector.

Tucker Quirk completed their Bachelor of Science (B.S.) degree in Bioengineering with a Biomaterials Concentration from Clemson University College of Engineering, Computing and Applied Sciences. Tucker attended this university from 2009 to 2013. In 2011 to 2012, Tucker also went to Nanyang Technological University Singapore, although the information does not specify if they obtained a degree from there. Prior to their university education, Tucker attended St. Sebastian's School from 2003 to 2009, but no specific degree or field of study is mentioned. Additionally, Tucker obtained a certification in Valuation and Financial Modeling Training Course from the Investment Banking Institute - iBanking.com in June 2015.

Links

Previous companies

Clemson University logo
HealthCare Royalty logo
Nomura logo

Org chart

Peers

Timeline

  • Vp, Business Development

    December 1, 2023 - present

  • Senior Director Business Development

    December 1, 2022

  • Business Development

    September, 2021

View in org chart